Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943944 | 0.86 | HTR6 (0.30) | HTR2AHTR6 | |
| SCHEMBL3380394 | 0.80 | HTR2A (0.35) | HTR2AHTR6 | |
| SCHEMBL9222381 | 0.80 | HTR2A (0.35) | HTR2AHTR6 | |
| SCHEMBL7947949 | 0.80 | HTR6 (0.39) | HTR2AHTR6 | |
| SCHEMBL7095115 | 0.79 | HTR6 (0.33) | HTR2AHTR6 | |
| SCHEMBL28978370 | 0.79 | HTR6 (0.33) | HTR2AHTR6 | |
| SCHEMBL30577433 | 0.79 | HTR2A (0.40) | HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL2901254 | 0.78 | HTR2A (0.34) | HTR2AHTR6 | |
| SCHEMBL9280884 | 0.77 | HTR6 (0.33) | HTR2AHTR6 | |
| SCHEMBL2763485 | 0.77 | SIGMAR1 (0.35) | HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5945553-A | Process for preparing a methylene-bridged biscyclopentadienyl compound | TARGOR GMBH (DE) | 1999-08-31 | — | — | US | claimed |
| JP-5043624-A | — | — | None | — | — | JP | disclosed |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11491179-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | URIGEN PHARMACEUTICALS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10421921-B2 | Lubricants from mixed alpha-olefin feeds | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018191412-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-0566349-A2 | Process for producing alpha-olefin polymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-5252677-A | Epoxy, hydroxy or sulfonic acid end groups | MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) | 1993-10-12 | — | — | US | disclosed |
| EP-0553491-A1 | Catalyst for polymerization of olefins and process for production of olefin polymers | TOSOH CORPORATION (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5225501-A | Transition metal compound and alumoxane catalyst | MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) | 1993-07-06 | — | — | US | disclosed |
| JP-H0543624-A | PRODUCTION OF MINUTE POLYPROPYLENE PARTICLE | MITSUBISHI PETROCHEM CO LTD | 1993-02-23 | — | — | JP | disclosed |
| EP-0512741-A1 | Process for producing a propylene random copolymer | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-11-11 | — | — | EP | disclosed |
| EP-0511846-A1 | Aminated olefin polymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-11-04 | — | — | EP | disclosed |
| EP-0487278-A2 | Functionalized olefin polymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5003019-A | Radiation transparent, heat resistant, solvent resistant copolymer | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| EP-0283164-A2 | Cyclo-olefinic random copolymer, olefinic random copolymer, and process for producing cyclo-olefinic random copolymers | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | HTR2A 2553/4885HTR6 2080/4885 |
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | HTR2A 2553/4885HTR6 2080/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | HTR2A 2553/4885HTR6 2080/4885 |
| US-11491179-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | HTR2A 2553/4885HTR6 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.